These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34013740)
1. Representation of Women Authors in Trials of Lipid-Lowering Therapy. Raghu Subramanian C; Khan SU; Lone AN; Reza N; DeFilippis EM; Gulati M; Michos ED J Am Heart Assoc; 2021 Jun; 10(11):e020663. PubMed ID: 34013740 [No Abstract] [Full Text] [Related]
2. Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials? Bansal M; Agarwala R Indian Heart J; 2018; 70(3):331-334. PubMed ID: 29961445 [No Abstract] [Full Text] [Related]
4. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease. Temple R Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896 [No Abstract] [Full Text] [Related]
5. Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent? Masana L Clin Investig Arterioscler; 2017; 29(6):278-279. PubMed ID: 29173491 [No Abstract] [Full Text] [Related]
7. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. Navar AM; Wang TY; Goldberg AC; Robinson JG; Roger VL; Wilson PF; Virani SS; Elassal J; Lee LV; Webb LE; Peterson E Am Heart J; 2015 Nov; 170(5):865-71. PubMed ID: 26542493 [TBL] [Abstract][Full Text] [Related]
8. Terje Pedersen: a pioneer trialist in preventive cardiology. Morris K Lancet; 2010 Feb; 375(9716):717. PubMed ID: 20189014 [No Abstract] [Full Text] [Related]
9. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Graham I; Shear C; De Graeff P; Boulton C; Catapano AL; Stough WG; Carlsson SC; De Backer G; Emmerich J; Greenfeder S; Kim AM; Lautsch D; Nguyen T; Nissen SE; Prasad K; Ray KK; Robinson JG; Sasiela WJ; Bruins Slot K; Stroes E; Thuren T; Van der Schueren B; Velkovski-Rouyer M; Wasserman SM; Wiklund O; Zouridakis E; Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):119-127. PubMed ID: 29194462 [TBL] [Abstract][Full Text] [Related]
10. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. Danchin N; Simon T Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045 [No Abstract] [Full Text] [Related]
11. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Giugliano RP; Mach F; Zavitz K; Kurtz C; Schneider J; Wang H; Keech A; Pedersen TR; Sabatine MS; Sever PS; Honarpour N; Wasserman SM; Ott BR; Clin Cardiol; 2017 Feb; 40(2):59-65. PubMed ID: 28207168 [TBL] [Abstract][Full Text] [Related]